Sublingual Antipsychotic Formulations
Asenapine is the primary antipsychotic available in a sublingual formulation, approved for schizophrenia and bipolar I disorder (manic or mixed episodes). 1
Available Sublingual Antipsychotics
Asenapine (FDA-Approved)
- Commercially available sublingual formulation specifically designed due to extensive first-pass metabolism if swallowed 1
- Approved for schizophrenia and manic/mixed episodes of bipolar I disorder
- Available generically 1
- Requires placement under the tongue with no food or drink for 10 minutes after administration 1
- Twice-daily dosing required 1
Common adverse effects include:
- Dysgeusia (altered/unpleasant taste)
- Oral hypoesthesia (numbness) 1
Off-Label Sublingual Use
Lorazepam tablets can be used sublingually (off-label) for anxiety or agitation 2:
- 0.5-1 mg sublingually four times daily as needed (maximum 4 mg/24 hours)
- Reduce to 0.25-0.5 mg in elderly/debilitated patients (maximum 2 mg/24 hours) 2
Orally Disintegrating Tablets (ODTs) - Important Distinction
Critical caveat: Several antipsychotics are available as orally disintegrating tablets (ODTs), but these are NOT true sublingual formulations 3:
These ODTs are swallowed and enter circulation via the portal system—they do not have more rapid onset than standard oral tablets. They are useful primarily for patients who might divert medication, not for sublingual absorption 3.
Clinical Considerations
When to Consider Sublingual Formulations
Sublingual routes are advantageous when:
- Rapid onset of action is needed
- First-pass metabolism is problematic
- Patient cooperation exists but swallowing is difficult 5, 3
- Avoiding gastrointestinal degradation is necessary 5
Limitations
Sublingual asenapine requires patient cooperation and has specific restrictions that may limit adherence:
- Food/drink restrictions (10-minute wait)
- Twice-daily dosing
- Taste disturbances and oral numbness 1
For acute agitation requiring rapid tranquilization, other routes may be more appropriate:
- Intramuscular formulations (haloperidol, olanzapine, ziprasidone, aripiprazole) 4, 6
- Inhaled loxapine (FDA-approved for acute agitation) 3
- Intranasal midazolam 3
Research Pipeline
Iloperidone sublingual films are under investigation but not yet commercially available 7. Other antipsychotics are being explored for sublingual delivery, but asenapine remains the only FDA-approved sublingual antipsychotic formulation currently available 5.